APVO vs. MBRX, LIXT, CHRO, XFOR, TRAW, EVOK, TSBX, BFRI, OBSV, and BMRA
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Moleculin Biotech (MBRX), Lixte Biotechnology (LIXT), Chromocell Therapeutics (CHRO), X4 Pharmaceuticals (XFOR), Traws Pharma (TRAW), Evoke Pharma (EVOK), Turnstone Biologics (TSBX), Biofrontera (BFRI), ObsEva (OBSV), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry.
Aptevo Therapeutics vs. Its Competitors
Moleculin Biotech (NASDAQ:MBRX) and Aptevo Therapeutics (NASDAQ:APVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability.
Moleculin Biotech has a beta of 1.38, suggesting that its stock price is 38% more volatile than the S&P 500. Comparatively, Aptevo Therapeutics has a beta of 5.58, suggesting that its stock price is 458% more volatile than the S&P 500.
Moleculin Biotech has higher earnings, but lower revenue than Aptevo Therapeutics.
Moleculin Biotech's return on equity of -278.80% beat Aptevo Therapeutics' return on equity.
15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 8.1% of Aptevo Therapeutics shares are held by institutional investors. 2.1% of Moleculin Biotech shares are held by company insiders. Comparatively, 0.0% of Aptevo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Moleculin Biotech presently has a consensus target price of $4.00, indicating a potential upside of 398.75%. Aptevo Therapeutics has a consensus target price of $219,040.00, indicating a potential upside of 7,228,942.90%. Given Aptevo Therapeutics' higher possible upside, analysts clearly believe Aptevo Therapeutics is more favorable than Moleculin Biotech.
In the previous week, Moleculin Biotech had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 2 mentions for Moleculin Biotech and 1 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.94 beat Moleculin Biotech's score of 0.64 indicating that Aptevo Therapeutics is being referred to more favorably in the news media.
Summary
Moleculin Biotech beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.
Get Aptevo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptevo Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:APVO) was last updated on 7/18/2025 by MarketBeat.com Staff
Free APVO Stock Alerts